Galectin Therapeutics Inc.
NASDAQ:GALT
1.15 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Galectin Therapeutics Inc. |
Symbool | GALT |
Munteenheid | USD |
Prijs | 1.15 |
Beurswaarde | 71,654,315 |
Dividendpercentage | 0% |
52-weken bereik | 0.73 - 4.27 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Joel Lewis |
Website | https://galectintherapeutics.com |
An error occurred while fetching data.
Over Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)